NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call
NeuroMetrix (NURO) will release its Q4 and full-year 2020 financial results on January 28, 2021, before market openings. A conference call is set for 8:00 a.m. ET that same day to discuss these results and related business developments. Investors can access the call by dialing specific numbers for domestic and international participants. The call will be replayed for a week post-event. NeuroMetrix specializes in innovative medical devices for nervous system disorders, offering products like DPNCheck®, ADVANCE™, and Quell®.
- Upcoming earnings report may provide insights into revenue and growth metrics.
- Product offerings include DPNCheck®, ADVANCE™, and Quell® for market differentiation.
- None.
WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of the market on January 28, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on January 28, 2021 to discuss its financial results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 8694435. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.
A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 8694435. The replay will be available for one week after the conference call.
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE™ is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter. For more information, visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
FAQ
When will NeuroMetrix release its Q4 financial results?
What time is the conference call for NeuroMetrix's earnings report?
How can I access the replay of NeuroMetrix's conference call?
What products does NeuroMetrix offer?
